Intercept Pharmaceuticals Inc. (ICPT)

69.99 -0.13 (-0.185%)

IEX Real-Time Price

May 22, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 70.12

Price Open 69.99

Volume: 416,167

Avg Volume: 636,400

Market Cap: 2.07B

P/E Ratio -5

52 Wk Range 51.05-135.59



ICPT Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-04-30
28.7M
5M
4.84
17.42%

2018-04-13
28.54M
5.95M
6.37
20.85%

2018-03-29
28.54M
7.02M
12.58
24.58%

2018-03-15
24.35M
6.91M
10.16
28.40%




ICPT Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-08
Q1 2018
BTO
-3.41 (8)
-3.22
0.19

2018-05-03
Q1 2018
N/A
-3.42 (8)
0.00
0.00

2018-02-22
Q4 2017
N/A
-3.39 (10)
-4.43
-0.86

2018-02-14
Q4 2017
BTO
-3.57 (10)
-4.43
-0.86

News

Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side (2018-05-17 14:35 SeekingAlpha)

There can be no greater gift than that of giving ones time and energy to help others without expecting anything in return. Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the…

 

Intercept: Still Not 'Intercepting' At These Levels (2018-05-16 19:11 SeekingAlpha)

Intercept ( ICPT ) remains a highly uncertain play for investors. On the final days of 2017, I looked at the prospects for the firm noting that investors had many concerns going into 2018. The fact is that developments in recent years and into the future are subject to a fierce debate am…

 

Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments (2018-05-15 10:00 SeekingAlpha)

Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf…

 

Intercept Pharmaceuticals (ICPT) Q1 2018 Results - Earnings Call Transcript (2018-05-08 13:50 SeekingAlpha)

Intercept Pharmaceuticals, Inc. (ICPT) Q1 2018 Earnings Call May 08, 2018 8:30 am ET Executives Mark Vignola - Intercept Pharmaceuticals, Inc. Mark Pruzanski - Intercept Pharmaceuticals, Inc. Richard Kim - Intercept Pharmaceuticals, Inc. Lisa Bright - Intercept Pharmaceuticals,…

 

Intercept Pharma beats by $0.19, misses on revenue (2018-05-08 07:09 SeekingAlpha)

Intercept Pharma (NASDAQ: ICPT ): Q1 EPS of -$3.22 beats by $0.19 . More news on: Intercept Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more …

 


Statistics

Shares Outstanding: 29.58M

Top 15 Institution Percent: 88.10

Price To Sales: 14.44

Price To Book: 128.60

Revenue: 109.91M

Gross Profit: 108.63M

Cash: 1.46B

Debt: N/A

Return On Assets: -66.31

Return On Equity: -374.57

Profit Margin: N/A

Price History

Beta: -1.73

50-day Moving Avg: 67.87

200-day Moving Avg: 70.91

YTD Change: 24.44

5-day Change: -1.56

1-month Change: 3.57

3-month Change: 18.59

6-month Change: 13.46

1-year Change: -38.34

Revenue Per Share: 4.00

Revenue Per Employee: 216781.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Intercept Pharmaceuticals Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need.